(Q50464042)

14 March 2018

title

Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. (English)

1 reference

14 March 2018

1 reference

1 reference

Brian H Kushner

1

1 reference

14 March 2018

Amy Budnick

2

1 reference

14 March 2018

Kim Kramer

3

1 reference

14 March 2018

Shakeel Modak

4

1 reference

14 March 2018

Nai-Kong V Cheung

5

1 reference

14 March 2018

language of work or name

English

0 references

publication date

1 July 2006

1 reference

14 March 2018

published in

Cancer

1 reference

14 March 2018

volume

107

1 reference

14 March 2018

issue

2

1 reference

14 March 2018

page(s)

417-422

1 reference

14 March 2018

Ototoxicity of cisplatinum in children and adolescents

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22004

High-dose rapid schedule chemotherapy for disseminated neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22004

7 January 2021

Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22004

7 January 2021

Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22004

7 January 2021

Phase I topotecan preparative regimen for high-risk neuroblastoma, high-grade glioma, and refractory/recurrent pediatric solid tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22004

7 January 2021

Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22004

7 January 2021

Treatment of High-Risk Neuroblastoma With Triple-Tandem High-Dose Therapy and Stem-Cell Rescue: Results of the Chicago Pilot II Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22004

7 January 2021

Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22004

7 January 2021

Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22004

7 January 2021

The incidence of hearing impairment after successful treatment of neuroblastoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22004

7 January 2021

Long-term renal and hearing toxicity of carboplatin in infants treated for localized and unresectable neuroblastoma: results of the SFOP NBL90 study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22004

7 January 2021

Platinum Compound-Related Ototoxicity in Children: Long-Term Follow-Up Reveals Continuous Worsening of Hearing Loss.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22004

7 January 2021

Cisplatin-induced ototoxicity in osteosarcoma patients: a report from the late effects surveillance system.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22004

7 January 2021

Ototoxicity of preradiation cisplatin for children with central nervous system tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22004

7 January 2021

Ototoxic effect of cisplatin in children with brain tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22004

7 January 2021

Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22004

7 January 2021

Ototoxicity in children with malignant brain tumors treated with the "8 in 1" chemotherapy protocol.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22004

7 January 2021

Radiotherapy enhanced ototoxicity of cisplatin in children.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22004

7 January 2021

Hearing loss in children receiving cisplatin chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22004

7 January 2021

cis-platinum ototoxicity in children.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22004

7 January 2021

Cisplatin ototoxicity in children: a practical grading system.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22004

7 January 2021

cis-platinum ototoxicity in children.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22004

7 January 2021

Cisplatin in children: hearing loss correlates with iris and skin pigmentation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22004

7 January 2021

Ototoxic impact of cisplatin in pediatric oncology patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22004

7 January 2021

Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22004

7 January 2021

Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22004

7 January 2021

Clinical evaluation of sequentially scheduled cisplatin and VM26 in neuroblastoma: response and toxicity.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22004

7 January 2021

A phase II study of high-dose cisplatin and VP-16 in neuroblastoma: a report from the Société Française d'Oncologie Pédiatrique

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22004

7 January 2021

Very-high-dose cisplatin and etoposide in children with untreated advanced neuroblastoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22004

7 January 2021

Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach--results of the first prospective study of the International Society of Pediatric Oncology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22004

7 January 2021

Acute onset deafness in a 4-year-old girl after a single infusion of cis-platinum.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22004

7 January 2021

Pathophysiology of the ototoxicity of cis-diamminedichloroplatinum

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22004

7 January 2021

Identifiers

DOI

10.1002/CNCR.22004

1 reference

14 March 2018

PubMed ID

16779793

1 reference

14 March 2018